Loading...
•
Jun 30, 2021
OrthoPediatrics Q2 2021 Earnings Report
OrthoPediatrics experienced significant revenue growth, driven by strong domestic performance and international expansion.
Key Takeaways
OrthoPediatrics reported a 96% increase in total revenue for Q2 2021, reaching $26.7 million, compared to $13.6 million in Q2 2020. The company saw robust growth in both U.S. and international markets, with U.S. revenue increasing by 79% and international revenue increasing by 243%.
Total revenue increased by 96% year-over-year, reaching $26.7 million.
U.S. revenue grew by 79%, representing 81.4% of total revenue.
International revenue increased by 243%, representing 18.6% of total revenue.
Gross profit margin improved to 76.6% compared to 74.0% in the same period last year.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma & Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is increasing its full year revenue guidance range to $97 to $101 million, up from $94 to $98 million, representing 36% to 42% growth over 2020 revenue.
Positive Outlook
- Increased full year 2021 revenue guidance from $94-$98 million to $97-$101 million
- Strong momentum in the U.S.
- Expecting 36% to 42% growth over 2020 revenue.
Challenges Ahead
- Potential headwinds resulting from the COVID-19 Delta variant.
- Expect regional variability to persist in international markets.
- Hospitals continue to work through backlogs.
- Countries face challenges with COVID-19 surges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income